---
title: "ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297826808.md"
description: "Preliminary clinical proof of concept achieved for lead candidate in pruritic diseases, with multiple pipeline programs advancing toward clinical trials. IPO proceeds of $332.4 million extend cash runway into 2030, supporting robust R&D investment and operational growth.Original document: Attovia Therapeutics, Inc. [ATTO] SEC 8-K Current Report — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-02T20:24:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297826808.md)
  - [en](https://longbridge.com/en/news/297826808.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297826808.md)
generator: "portal-rs"
---

# ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030

Preliminary clinical proof of concept achieved for lead candidate in pruritic diseases, with multiple pipeline programs advancing toward clinical trials. IPO proceeds of $332.4 million extend cash runway into 2030, supporting robust R&D investment and operational growth.

Original document: Attovia Therapeutics, Inc. \[ATTO\] SEC 8-K Current Report — Sep. 2 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md)

## Related News & Research

- [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md)
- [Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway](https://longbridge.com/en/news/297940103.md)
- [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End  on September 14th](https://longbridge.com/en/news/298168859.md)
- [Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating](https://longbridge.com/en/news/297636916.md)
- [13:18 ETNew study: Professionals say AI is already reshaping research hiring, and early-career roles are the most exposed](https://longbridge.com/en/news/297943716.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**